Effect of cholecystectomy on liver fat and fibrosis in metabolic dysfunction-associated steatotic liver disease patients

doi:10.4292/wjgpt.v17.i2.114876

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 2

This Article

(29)

(26)

(0)

(472)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Pharmacology and Therapeutics

ISSN

2150-5349

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Prospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastrointest Pharmacol Ther. Jun 5, 2026; 17(2): 114876
Published online Jun 5, 2026. doi: 10.4292/wjgpt.v17.i2.114876

Table 2 Biological and histological data, n (%)/median (interquartile range)/mean ± SE

Scores M0	Total (n = 213), mean (extreme)	Chx+ (n = 103), mean (extreme)	Chx- (n = 110), mean (extreme)	P value
BARD score	2.74 (0-4)	2.76 ± 1.04	2.72 (0-4)	0.79
HOMA test	7.879 (1.0-18.7)	7.37 ± 2.52	8.32 (2-18.7)	0.023
FLI score	78.52 (7-100)	75.71 ± 17.62	81.15 (31-100)	0.016
LAP score	82.73 (15.-372.40)	82.5 ± 40.09	82.94 (20.1-372.4)	0.94
HSI score	42.88 (25.2-79.4)	40.62 ± 5.76	44.99 (29.1-79.4)	< 0.001
APRI score	0.33 (0.1-2.8)	0.34 ± 0.32	0.33 (0.1-0.7)	0.67
FIB 4 score	2.64 (0.25-283.00)	4.16 ± 2.77	1.22 (0.25-3.73)	0.26
NFS score	-1.13 (-6.57 to 3.36)	-1.10 ± 1.44	-1.16 (-6.57 to 3.36)	0.78
Length LB (mm)	22.27 (10-45)	23.10 (10-45)	22.89 (10-45)	0.16
Portal area (n)	15.99 (6-28)	15.19 (6-28)	16.74 (7-28)	0.036
Steatosis (%)	29.53 (5-70)	23.79 (5-70)	34.90 (5-70)	< 0.001
NAS score	4.51 (1-8)	3.93 (1-8)	5.05 (2-8)	< 0.001
SAF score	6.36 (2-11)	5.56 (2-11)	7.11 (3-11)	< 0.001
Steatosis grade: S0	5 (2.3)	5 (4.9)	0	< 0.001
S1	114 (53.5)	68 (66)	46 (41.8)	< 0.001
S2	81 (38.0)	28 (27.2)	53 (48.2)	< 0.001
S3	13 (6.1)	2 (1.9)	11 (10)	< 0.001
Steatosis type: Absent	4 (1.9	4 (3.9)	0 (0)	0.007
Pure macrolobular	18 (8.5)	12 (11.7)	6 (5.5)	0.004
Pure microlobular	7 (3.3)	6 (5.8)	1 (0.9)	0.21
Mixed	184 (86.4)	81 (78.6)	103 (93.6)	0.003
Ballooning: Absent	23 (10.8)	15 (14.6)	8 (7.3)	0.001
Present (size = hepatocyte)	57 (26.8)	37 (35.9)	20 (18.2)	0.001
Present (size = hepatocyte 2n)	133 (62.4)	51 (49.5)	82 (74.5)	0.001
Apoptotic bodies: Absent or rare	162 (76.1)	89 (86.4)	73 (66.4)	0.001
Present	51 (23.9)	14 (13.6)	37 (33.6)	0.001
Mallory’s body: Absent	160 (75.1)	88 (85.4)	72 (65.5)	0.003
Present	52 (24.4)	15 (14.6)	37 (33.6)	0.003
Lobular inflammation: 0 foyer	21 (9.9)	14 (13.6)	7 (6.5)	< 0.001
1à 2 foyers	93 (43.7)	58 (56.3)	35 (31.8)	< 0.001
3 à 4 foyers	99 (46.5)	24 (23.3)	46 (41.8)	< 0.001
Portal inflammation: Absent	18 (8.5)	11 (10.7)	7 (6.4)	0.32
Present	195 (91.5)	92 (89.3)	103 (93.6)	0.32
MASH: Present	80 (37.6)	32 (31.06)	48 (43.63)	0.06
Absent	133 (62.4)	71 (68.9)	62 (56.4)	0.06
Classification Metavir (activity): Stade A1	54 (25.4)	34 (33.0)	20 (18.2)	< 0.001
Stade A2	135 (63.4)	66 (64.1)	69 (62.7)	< 0.001
Stade A3	24 (11.3)	3 (2.9)	21 (19.1)	< 0.001
Classification Metavir (fibrosis): Stade F0	6 (2.8)	5 (4.9)	1 (0.9)	< 0.001
Stade F1	29 (13.6)	24 (23.3)	5 (4.5)	< 0.001
Stade F2	144 (67.6)	67 (65.0)	77 (70)	< 0.001
Stade F3	26 (12.2)	5 (4.9)	21 (19.1)	< 0.001
Stade F4	8 (3.8)	2 (1.9)	6 (5.5)	< 0.001
Stiffness (kPa) MED	8.5 (5.3-24.5)	7.69 (5.3-14.2)	9.25 (7.2-24.5)	< 0.001
CAP (dB/m) MED	312.91 (180-400)	300.85 (180-400)	324.20 (224-400)	< 0.001
Elasticity (m/second)	1.11 (0.59-2.94)	1.01 (0.59-2.14)	1.20 (0.73-2.94)	< 0.001
Steatosis (%)	16.46 (3-50)	14.22 (3-40)	18.55 (4-50)	< 0.001

Chx: Cholecystectomy; BARD: Body mass index, aspartate aminotransferase/alanine aminotransferase ratio, diabetes mellitus; HOMA: Homeostasis model assessment; FLI: Fatty liver index; LAP: Lipid accumulation product; HSI: Hepatic steatosis index; APRI: Aspartate aminotransferase/platelet ratio index; FIB4: Fibrosis 4; NFS: Non-alcoholic fatty liver disease fibrosis score; LB: Liver biopsy; NAS: Non-alcoholic steatohepatitis activity score; MASH: Metabolic dysfunction-associated steatohepatitis; SAF: Steatosis, activity and fibrosis score; MED: Median stemness; CAP: Controlled attenuation parameter.

Full Size Table

Citation: Amalou K, Belal N, Tibouk A, Ghedada Y, Rekab R, Fadel S, Debzi N, Bousloub A. Effect of cholecystectomy on liver fat and fibrosis in metabolic dysfunction-associated steatotic liver disease patients. World J Gastrointest Pharmacol Ther 2026; 17(2): 114876
URL: https://www.wjgnet.com/2150-5349/full/v17/i2/114876.htm
DOI: https://dx.doi.org/10.4292/wjgpt.v17.i2.114876

Amalou K, Belal N, Tibouk A, Ghedada Y, Rekab R, Fadel S, Debzi N, Bousloub A. Effect of cholecystectomy on liver fat and fibrosis in metabolic dysfunction-associated steatotic liver disease patients. World J Gastrointest Pharmacol Ther 2026; 17(2): 114876 [PMID: 42273239 DOI: 10.4292/wjgpt.v17.i2.114876]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.